The Effects of TNF-alpha Inhibitor Therapy on the Incidence of Infection in JIA Children: a Meta-analysis

Overview

Journal Pediatr Rheumatol Online J

Publisher Biomed Central

Specialty Pediatrics

Date 2019 Jan 20

PMID 30658717

Citations 14

Authors

Arnold Nagy

Peter Matrai

Peter Hegyi

Hussain Alizadeh

Judit Bajor

Laszlo Czopf

Zoltan Gyongyi

Zoltan Kiss

Katalin Marta

Maria Simon

Agnes Lilla Szilagyi

Gabor Veres

Bernadett Mosdosi

Affiliations

Soon will be listed here.

Abstract

Background: Juvenile Idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. The diagnosis is based on the underlying symptoms of arthritis with an exclusion of other diseases Biologic agents are increasingly used on the side of disease-modifying anti-rheumatic drugs (DMARD) in JIA treatment.

Main Body: The aim of this meta-analysis was to investigate the observed infections in JIA children during tumor necrosis factor (TNF)-alpha inhibitor therapy. A systematic search of three databases (Medline via PubMed, Embase, Cochrane Library) was carried out up to May 2018. Published trials that evaluated the infectious adverse events in patients receiving TNF-alpha inhibitor vs. a control group were included in the analysis. Full-text data extraction was carried out independently by the investigators from ten relevant publications. 1434 patients received TNF-alpha inhibitor therapy; the control group consisted of 696 subjects. The analysis presented the risk of infection in the active treatment group (OR = 1.13; 95% CI: 0.76-1.69; p = 0.543). The majority of infections were upper respiratory tract infections (URTIs). Furthermore, the subgroup analysis demonstrated a higher infection rate in the observed localization.

Conclusion: Anti-TNF therapy slightly but not significantly increases the incidence of infection in JIA children compared to other therapies (GRADE: moderate evidence). The most common infections reported were mild URTIs. Further studies with larger patients number with a strong evidence level are crucially needed to finalize the answer whether anti-TNF therapy elevates and if yes on what extent the incidence of infection in JIA children.

Trial Registration: Prospero: CRD42017067873 .

Citing Articles

Tuberculosis in children and adolescents with rheumatic diseases using biologic agents: an integrative review.

Lima L, Aurilio R, Fonseca A, Parente A, SantAnna M, SantAnna C Rev Paul Pediatr. 2023; 42:e2022084.

PMID: 37436237 PMC: 10332438. DOI: 10.1590/1984-0462/2024/42/2022084.

and seropositivity in juvenile idiopathic arthritis and its relation to disease activity and type of therapies.

Salem D, Al-Ghamdi A, Alghamdi J, Ismail A, Alghamdi B, Abdelrazek E Food Waterborne Parasitol. 2023; 31:e00195.

PMID: 37256200 PMC: 10225886. DOI: 10.1016/j.fawpar.2023.e00195.

Complexity of the Immune Response Elicited by Different COVID-19 Vaccines, in the Light of Natural Autoantibodies and Immunomodulatory Therapies.

Borocz K, Kinyo A, Simon D, Erdo-Bonyar S, Nemeth P, Berki T Int J Mol Sci. 2023; 24(7).

PMID: 37047412 PMC: 10094397. DOI: 10.3390/ijms24076439.

Vaccination coverage in children with juvenile idiopathic arthritis, inflammatory bowel diseases, and healthy peers: Cross-sectional electronic survey data.

Makarova E, Khabirova A, Volkova N, Gabrusskaya T, Ulanova N, Sakhno L World J Clin Pediatr. 2023; 12(2):45-56.

PMID: 37034429 PMC: 10075019. DOI: 10.5409/wjcp.v12.i2.45.

An empirical comparison of the harmful effects for randomized controlled trials and non-randomized studies of interventions.

Dai M, Furuya-Kanamori L, Syed A, Lin L, Wang Q Front Pharmacol. 2023; 14:1064567.

PMID: 37025494 PMC: 10070801. DOI: 10.3389/fphar.2023.1064567.

References

Lovell D, Giannini E, Reiff A, Cawkwell G, Silverman E, Nocton J . Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000; 342(11):763-9. DOI: 10.1056/NEJM200003163421103. View

Keane J, Gershon S, Wise R, Kasznica J, Schwieterman W, Siegel J . Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001; 345(15):1098-104. DOI: 10.1056/NEJMoa011110. View

Doran M, Crowson C, Pond G, OFallon W, Gabriel S . Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002; 46(9):2287-93. DOI: 10.1002/art.10524. View

Doran M, Crowson C, Pond G, OFallon W, Gabriel S . Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002; 46(9):2294-300. DOI: 10.1002/art.10529. View

Fendrick A, Monto A, Nightengale B, Sarnes M . The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med. 2003; 163(4):487-94. DOI: 10.1001/archinte.163.4.487. View

Lahdenne P, Vahasalo P, Honkanen V . Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis. 2003; 62(3):245-7. PMC: 1754468. DOI: 10.1136/ard.62.3.245. View

Gomez-Reino J, Carmona L, Rodriguez Valverde V, Martin Mola E, Montero M . Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003; 48(8):2122-7. DOI: 10.1002/art.11137. View

Lovell D, Zaoutis T, Sullivan K . Immunosuppressants, infection, and inflammation. Clin Immunol. 2004; 113(2):137-9. DOI: 10.1016/j.clim.2004.03.010. View

Smith J, Thompson D, Whitcup S, Suhler E, Clarke G, Smith S . A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005; 53(1):18-23. DOI: 10.1002/art.20904. View

10.

Merino R, de Inocencio J, Garcia-Consuegra J . Evaluation of revised International League of Associations for Rheumatology classification criteria for juvenile idiopathic arthritis in Spanish children (Edmonton 2001). J Rheumatol. 2005; 32(3):559-61. View

11.

Wheat L . Histoplasmosis: a review for clinicians from non-endemic areas. Mycoses. 2006; 49(4):274-82. DOI: 10.1111/j.1439-0507.2006.01253.x. View

12.

Askling J, Fored C, Brandt L, Baecklund E, Bertilsson L, Feltelius N . Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis. 2007; 66(10):1339-44. PMC: 1994293. DOI: 10.1136/ard.2006.062760. View

13.

Bernatsky S, Hudson M, Suissa S . Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford). 2007; 46(7):1157-60. DOI: 10.1093/rheumatology/kem076. View

14.

Ruperto N, Lovell D, Cuttica R, Wilkinson N, Woo P, Espada G . A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007; 56(9):3096-106. DOI: 10.1002/art.22838. View

15.

Smitten A, Choi H, Hochberg M, Suissa S, Simon T, Testa M . The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008; 35(3):387-93. View

16.

Horneff G, De Bock F, Foeldvari I, Girschick H, Michels H, Moebius D . Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis. 2008; 68(4):519-25. DOI: 10.1136/ard.2007.087593. View

17.

Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650):924-6. PMC: 2335261. DOI: 10.1136/bmj.39489.470347.AD. View

18.

Lovell D, Reiff A, Ilowite N, Wallace C, Chon Y, Lin S . Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008; 58(5):1496-504. DOI: 10.1002/art.23427. View

19.

Lovell D, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K . Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008; 359(8):810-20. DOI: 10.1056/NEJMoa0706290. View

20.

Giannini E, Ilowite N, Lovell D, Wallace C, Rabinovich C, Reiff A . Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009; 60(9):2794-804. DOI: 10.1002/art.24777. View